VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | Using AI to predict light chain amyloidosis in patients with MGUS and SMM

Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter